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Background: Voriconazole exhibits in vitro activity against Candida glabrata and Candida krusei (EUCAST/CLSI
epidemiological cut-off values 1/0.25 and 1/0.5 mg/L, respectively). Yet, EUCAST found insufficient evidence to
set breakpoints for these species. We explored voriconazole pharmacodynamics (PD) in an in vitro dynamic
model simulating human pharmacokinetics (PK).
Methods: Four C. glabrata and three C. krusei isolates (voriconazole EUCAST and CLSI MICs of 0.03–2 mg/L) were
tested in the PK/PD model simulating voriconazole exposures (t1=2 6 h q12h dosing for 3 days). PK/PD break-
points were determined calculating the PTA for exposure indices fAUC0–24/MIC associated with half-maximal
activity (EI50) using Monte Carlo simulation analysis.
Results: Fungal load increased from 3.60±0.35 to 8.41±0.24 log10 cfu/mL in the drug-free control, with a max-
imum effect of 1 log10 kill of C. glabrata and C. krusei isolates with MICs of 0.06 and 0.25 mg/L, respectively, at
high drug exposures. The 72 h log10 cfu/mL change versus fAUC0–24/MIC relationship followed a sigmoid curve
for C. glabrata (R2=0.85–0.87) and C. krusei (R2=0.56–0.76) with EI50 of 49 (32–76) and 52 (33–78) fAUC/MIC for
EUCAST and 55 (31–96) and 80 (42–152) fAUC/MIC for CLSI, respectively. The PTAs for C. glabrata and C. krusei
isolates with EUCAST/CLSI MICs 0.125/0.06 mg/L were >95%. Isolates with EUCAST/CLSI MICs of 0.25–1/
0.125–0.5 would require trough levels 1–4 mg/L; isolates with higher MICs would not attain the corresponding
PK/PD targets without reaching toxicity.
Conclusions: The in vitro PK/PD breakpoints for C. glabrata and C. krusei for EUCAST (0.125 mg/L) and CLSI
(0.06 mg/L) bisected the WT populations. Trough levels of >4 mg/L, which are not clinically feasible, are neces-
sary for efficacy against WT isolates.
Introduction
The incidence of candidaemia has increased in recent years due to
numerous factors, most important being the exposure to broad-
spectrum antimicrobial agents, the use of aggressive therapies
such as cancer chemotherapy, use of indwelling vascular cathe-
ters, neutropenia, mucosal colonization of Candida spp. and prior
surgery.1,2 Although Candida albicans is the predominant cause of
invasive candidiasis, Candida glabrata is the second most common
species in northern Europe and America, and Candida krusei is
an important pathogen in cancer patients and patients with prior
fluconazole exposure.1,3
C. glabrata and C. krusei isolates demonstrate reduced
susceptibility or resistance to fluconazole. Echinocandins and
amphotericin B are thus first- and second-line agents, respectively,
against these pathogens.3,4 These two classes of antifungals are
available as IV formulations only and not suitable for outpatient
therapy. Furthermore, echinocandin resistance rates up to 15%
among clinical isolates of C. glabrata have been reported in some
settings, with a subset demonstrating an MDR phenotype, limiting
the therapeutic options even further.5
Voriconazole exhibits potent in vitro antifungal activity against
both C. glabrata and C. krusei isolates, with CLSI epidemiological
cut-off values (0.25 and 0.5 mg/L, respectively) being significantly
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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lower than those of fluconazole (8 and 32 mg/L, respectively)6
and close to the susceptibility breakpoint for voriconazole
against C. albicans (0.125 mg/L).7 However, EUCAST susceptibility
breakpoints have not been established due to a paucity of efficacy
data,8 and CLSI breakpoints have been proposed only for C. krusei
(0.5 mg/L) although with limited clinical data.9 Due to the small
number of patients with C. glabrata and C. krusei infections treated
with voriconazole, clinical efficacy–pharmacokinetic (PK)–MIC data
that might help describe exposure–effect relationships and deter-
mine clinical breakpoints are not foreseen to be collected in the
future.
In vitro PK/pharmacodynamic (PD) models can offer an alterna-
tive reliable approach for the description of the exposure–effect
relationships, the determination of PK/PD susceptibility breakpoints
using Monte Carlo analysis and the estimation of target values for
therapeutic drug monitoring (TDM). This is especially attractive in
the case of voriconazole, which has complex PK properties and for
which TDM is recognized as an important component to ensure ef-
fective, but not toxic, therapy.10 In the present study, a previously
described in vitro PK/PD model11 was used in order to simulate
human voriconazole PK against C. glabrata and C. krusei isolates
with different voriconazole susceptibilities and to determine PK/PD
susceptibility breakpoints for EUCAST and CLSI methodologies.
Subsequently, voriconazole AUC and trough levels in serum neces-
sary for optimal treatment and minimal toxicity were determined
in relation to MICs.
Materials and methods
Candida isolates
Four clinical C. glabrata isolates and three clinical C. krusei isolates with
increasing voriconazole EUCAST12 and CLSI13 MICs ranging from 0.03 to
2 mg/L were studied. The median EUCAST and CLSI MICs were determined
after 24 h of incubation in triplicate experiments. The isolates were stored in
normal sterile saline with 10% glycerol at#70C and revived by subcultur-
ing on Sabouraud dextrose agar plates supplemented with gentamicin and
chloramphenicol (SDA; bioMe´rieux) to ensure purity and viability. Inoculum
suspensions were prepared in normal sterile saline from 24 h cultures and
adjusted to a final inoculum of 104 cfu/mL using a counting chamber. The
number of cfu was confirmed by quantitative cultures on SDA plates.
Antifungal drugs and medium
Pure powder of voriconazole (Pfizer Inc., Athens, Greece) was dissolved
in sterile DMSO (Carlo Erba Reactifs-SDS, Val de Reuil, France) and stock sol-
utions of 10 mg/mL were stored at #70C until use. The medium used in
the in vitro PK/PD model was RPMI 1640 medium (with L-glutamine, without
bicarbonate) buffered to pH 7.0 with 0.165 M MOPS and supplemented with
100 mg/L chloramphenicol (AppliChem GmbH, Darmstadt, Germany).
In vitro PK/PD model
A previously described two-compartment PK/PD diffusion/dialysis model
simulating in vivo PK11 was used. The model consists of an external com-
partment comprising a conical flask connected to a peristaltic pump
(Minipuls EvolutionV
R
, Gilson Inc.) and an internal compartment comprising
a 10 mL volume semi-permeable cellulose dialysis tube (mol. wt <20 kDa,
Spectra/PorV
R
Float-A-LyzerV
R
G2, Spectrum Laboratories Inc., Breda, The
Netherlands) inoculated with a 104 cfu/mL conidial suspension. Repeated
sampling of 100lL was made from the internal compartment in order to
ensure that drug concentrations in the internal compartment indeed mimic
voriconazole drug concentration profiles in human plasma. Samples were
stored at #70C until tested. Replicate experiments were conducted in
order to assess the reproducibility.
In vitro PK
In order to describe the exposure–effect relationship, different voriconazole
concentration–time profiles were simulated in the in vitro PK/PD model,
with fCmax of 7, 3.5, 1.75 and 0.8 mg/L and t1=2 of6 h.14 Voriconazole levels
were measured using a microbiological agar diffusion assay as previously
described with a voriconazole-susceptible Candida parapsilosis isolate.15
The lowest limit of detection was 0.25 mg/L and intraday/interday variation
was <15%. A concentration–time curve was generated for each simulated
dose and analysed by non-linear regression analysis using a one-
compartment model described by the equation Ct=C0e
#k/t, where
Ct (dependent variable) is the concentration of drug at a given time (t)
(independent variable), C0 is the initial concentration of the drug at t=0 h, e
is the physical constant 2.18 and k is the rate of drug removal. The t1=2 was
calculated using the equation t1=2=0.693/k and compared with the respect-
ive values observed in humans. Finally, the fAUC0–24 was calculated for
each simulated dosage by applying the trapezoidal rule.
In vitro PD
To estimate the fungal load inside the dialysis tubes (internal compart-
ment) of each voriconazole dosing regimen, 100lL samples were collected
at regular intervals up to 72 h, 10-fold serially diluted in normal saline and
subcultured on SDA plates. Plates were incubated at 30C for 24 h and colo-
nies were counted at each dilution. Dilutions that yielded 10–50 colonies
were used in order to determine the log10 cfu/mL at each timepoint and to
construct the time–kill curves. The lowest limit of detection was 10 cfu/mL.
PK/PD modelling
To determine the in vitro exposure–response relationship, the log10 cfu/mL
at t=0 h was subtracted from the log10 cfu/mL at 72 h and plotted over
the fAUC0–24/MIC ratio for each simulated dose and isolate. The data were
then analysed with non-linear regression analysis using the sigmoidal
model with variable slope (Emax model) described by the equation
E=(Emax#Emin)%EI
n/(EIn!EI50n)!Emin, where Emax is the maximum in-
crease in log10 cfu/mL of the drug-free control (kept constant at log10 cfu/
mL in the drug-free control), Emin is the minimum log10 cfu/mL found at
high drug exposures (kept constant at#1 log10 cfu/mL), EI is the exposure
index fAUC0–24/MIC, EI50 is the exposure index required to achieve 50% of
Emax#Emin and n is the slope of the dose–effect relationship (Hill coeffi-
cient). The goodness of fit of the Emax model was assessed by visual inspec-
tion of graphs, residuals analysis, post run’s test and R2. All data were
analysed using the statistics software package GraphPad Prism, version 5.0,
for Windows (GraphPad Software, San Diego, CA, USA).
Monte Carlo simulation
Monte Carlo simulation analysis was performed using the Normal random
number generator function of EXCEL (MS Office 2007) for 5000 patients
receiving the standard IV voriconazole dosage of 4 mg/kg IV or 300 mg or-
ally twice daily, which corresponds to a total mean±SD steady-state tAUC0–12
of 50.4±41.83 mgh/L.14 For the simulation analysis, the fAUC0–24 used was
calculated as 2%fAUC0–12, where fAUC0–12 was 21.4±17.57 mgh/L based on
the 42% unbound fraction of voriconazole in human serum.16 The PTA for
EI50 was estimated for isolates with MICs ranging from 0.008 to 4 mg/L and
PK/PD susceptibility breakpoints were determined. Previously published MIC
distribution data from CLSI17 and EUCAST8 were used. Since the uncertainty
of EI50 is important for Monte Carlo simulations and PTA analysis,
18 the
PTAs were determined for the mean and the upper and lower 95% CI limits
of EI50 estimated with non-linear regression analysis.
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Trough levels and MICs
The required trough levels in human serum necessary to attain the EI50s
were calculated for different MICs. For that reason, the previously described
relationship between serum tAUC and trough concentrations (tCmin),
namely tAUC0–12=7.011!12.687%tCmin,
19 was used taking into account
the 58% protein binding of voriconazole in human serum.16 The EUCAST
and CLSI MICs for C. glabrata and C. krusei at which the corresponding
PK/PD targets were attained were plotted against the tAUC0–12
and tCmin.
Results
MICs
The MICs for the included strains determined by EUCAST and CLSI
methodologies are shown in Table 1. Most MICs fell within one
2-fold dilution when comparing across the EUCAST and CLSI
methods, with an absolute agreement of 64%.
PK
Figure 1 shows the steady-state plasma PK profiles based on
human PK of twice-daily voriconazole dosages simulated in the
in vitro PK/PD model. The mean±SD t1=2 was 6.9±2.7 h, with fCmax
of 6.49±0.98, 3.84±0.30, 1.76±0.60 and 0.86±0.10 mg/L, and
AUC0–24 of 47.71±9.97, 28.12±5.82, 12.13±3.80 and 5.75±
1.84 mgh/L, respectively, for all species and strains.
PD
C. glabrata (Figure 2) and C. krusei (Figure 3) isolates in the drug-
free control grew from 3.60±0.35 log10 cfu/mL at 0 h to 8.41±0.24
log10 cfu/mL at 72 h. Voriconazole decreased the fungal load in the
tubes proportionally to the MIC for the isolates. The maximum
effect of voriconazole corresponded to an 1 log10 cfu/mL reduc-
tion from the initial inoculum. This was found at high voriconazole
exposures for the isolates with the lowest EUCAST MIC, which was
0.06 mg/L for C. glabrata and 0.25 mg/L for C. krusei.
The 72 h change in the log10 cfu/mL versus fAUC0–24/MIC
relationship for the C. glabrata and C. krusei isolates is displayed
in Figure 4. The relationship followed a sigmoid curve for both
species, but the relationship was much clearer for C. glabrata
(R2=0.85–0.87) than for C. krusei (R2=0.56–0.76). For C. glabrata,
curve fits and associated parameters of EUCAST- and CLSI-derived
methods were comparable, with mean (95% CI) EI50s of 49
(32–76) and 55 (31–96) fAUC0–24/MIC, respectively. For C. krusei
isolates, the difference in results according to susceptibility
methods was more pronounced, with EI50 of 52 (33–78) for EUCAST
and 80 (42–152) for CLSI. EI50s determined from data at timepoints
earlier than 72 h were different from those at 72 h, in particular
for the 24 h timepoint (data not shown). This was mainly due to
the drug-free control not reaching its maximum growth (Figures 2
and 3).
Monte carlo analysis
The simulated patients had a mean±SD fAUC0–24 of
41.94±35.41 mgh/L, very close to previously published voricon-
azole exposures.14 The PTAs for 49 (32–76) and 52 (33–78) fAUC0–24/
Table 1. Median (range) of triplicate MICs (mg/L) for EUCAST and CLSI
for Candida isolates used in the present study
Isolate no. Reference code EUCAST CLSI
C. glabrata 3 SSI-W18236 0.06 (0.03–0.125) 0.03 (0.03)
C. glabrata 5 SSI-W17252 2 (1–4) 2 (2)
C. glabrata 9 SSI-W51696 0.5 (0.125–2) 0.5 (0.5)
C. glabrata 11 SSI-W42947 0.125 (0.125–0.25) 0.25 (0.125–0.25)
C. krusei 2 SSI-T5120 0.25 (0.125–0.25) 0.25 (0.25)
C. krusei 4 SSI-T3278 0.5 (0.5) 0.25 (0.25)
C. krusei 12 SSI-F49748 1 (0.125–2) 0.5 (0.125–0.5)
SSI, Statens Serum Institut.
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Figure 1. Representative concentration–time profiles of simulated q12h IV dosing regimens of voriconazole based on human PK in the in vitro PK/PD
model with target fCmax of 0.8, 1.75, 3.5 and 7 mg/L and obtained Cmin of 0.23, 0.67, 1.04 and 1.75 mg/L, respectively, and t1=2 of 6 h. Data represent
drug levels in the internal compartment of the in vitro model (solid lines) and the respective target values observed in human plasma (broken lines).
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MIC for EUCAST and 55 (31–96) and 80 (42–152) fAUC0–24/MIC
for CLSI for C. glabrata and C. krusei isolates with increasing MICs
are shown in Figure 5. The PTAs for the mean EI50 (solid black
lines) were >95%, 10%–95% and <10% for C. glabrata and C. krusei
isolates with EUCAST and CLSI MICs of0.125, 0.25–1 and2 mg/L,
whereas the PTAs for the upper 95% CI limit of EI50 (lower
broken black lines) were >95%, 10%–95% and <10% for C. glabrata
and C. krusei isolates with EUCAST MICs of 0.125, 0.25–1 and
2 mg/L and CLSI MICs of 0.06, 0.125–0.5 and 1 mg/L, respect-
ively (Figure 5).
Trough levels and MICs
The voriconazole trough levels in human serum required to attain
the corresponding PK/PD targets for C. glabrata and C. krusei iso-
lates with increasing EUCAST and CLSI MICs are shown in Figure 6.
The corresponding PK/PD targets could be attained for C. glabrata
and C. krusei isolates with EUCAST/CLSI MICs of 0.25–1/0.125–
0.5 mg/L, with trough levels of 1–4 mg/L. In contrast, for isolates
with higher MICs, trough levels of >5.5 mg/L, which are associated
with increased risk of toxicity,10 will be required.
Discussion
The present study showed that voriconazole PK/PD targets cannot
be attained for the vast majority of clinical C. glabrata and C. krusei
isolates with the standard doses. Based on the in vitro PK/PD tar-
gets determined in the present study for C. glabrata and C. krusei,
high PTAs were found only for isolates with EUCAST and CLSI MICs
of 0.125 and 0.06 mg/L, respectively. These PK/PD breakpoints
are two to three 2-fold dilutions lower than the corresponding epi-
demiological cut-off values for EUCAST (1 mg/L for both species)
and CLSI (0.25 mg/L for C. glabrata and 0.5 mg/L for C. krusei). This
questions the efficacy of voriconazole for those infections.
Voriconazole produced a small killing effect against C. glabrata
and C. krusei isolates (1 log10 reduction) at high drug exposures
against the most susceptible isolates also in line with previous
in vitro PK/PD studies for low-MIC isolates.20–22 For C. glabrata there
are no clinical breakpoints. The epidemiological cut-off values are
1 mg/L for EUCAST8 and 0.25 mg/L for CLSI.6 Based on the PK/PD
target determined in the present study (50 fAUC24/MIC), the cor-
responding PK/PD susceptibility breakpoint of 0.125 mg/L for
EUCAST and 0.06 mg/L for CLSI methodologies would bisect the
WT MIC distributions. The PD target could be attained for isolates
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Figure 2. Time–kill curves in the in vitro PK/PD model simulating q12h IV dosing regimens of voriconazole against C. glabrata isolates with fCmax of
0.8, 1.75 and 7 mg/L, and t1=2 of 6 h.
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with EUCAST/CLSI MICs of 0.25–1/0.125–0.5 mg/L, provided serum
trough levels of at least 1–4 mg/L were ensured, thus necessitating
TDM and dose adjustment in most cases. Previous animal studies
showed that voriconazole at 40 mg/kg once daily was effective at
reducing statistically significantly kidney fungal burden >1 log10
cfu/g (average 2 log10 cfu/g) compared with untreated controls
after 7 days of treatment against C. glabrata isolates with CLSI
MICs of 0.125 mg/L in grapefruit-fed neutropenic mice.23
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Figure 4. In vitro PK/PD relationship of voriconazole against C. glabrata and C. krusei isolates tested in the in vitro PK/PD model using EUCAST and CLSI
MICs. The mean (95% CI) fAUC0–24/MICs are shown for each species for EUCAST and CLSI.
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Figure 3. Time–kill curves in the in vitro PK/PD model simulating q12h IV dosing regimens of voriconazole against C. krusei isolates with fCmax of 0.8,
1.75, 3.5 and 7 mg/L, and t1=2 of 6 h.
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Voriconazole has been successfully used for C. glabrata infec-
tions,24,25 whereas breakthrough C. glabrata isolates have been
reported in patients with voriconazole trough levels0.63 mg/L.26
For C. krusei, the PD targets of 52 fAUC0–24/MIC for EUCAST and
80 fAUC0–24/MIC for CLSI were determined, suggesting a PK/PD
breakpoint of 0.125 and 0.06 mg/L, respectively, which are three
2-fold dilutions lower that the corresponding epidemiological
cut-off values of 1 mg/L (EUCAST) and 0.5 mg/L (CLSI).8,27
Currently, only CLSI has defined the susceptibility breakpoints of
susceptible/intermediate/resistant (S/I/R) 0.5/1/2 mg/L although
there are only a few cases (n=9) of invasive candidiasis caused by
C. krusei available for analysis.9 Of note, the response rate in
the latter study was 78% for isolates with CLSI MICs of 0.125 mg/L
(5/7) and 0.25 mg/L (2/2). However, the 0.125 mg/L breakpoint
again bisects the WT distributions of EUCAST and CLSI methods.
Voriconazole at 5 and 10 mg/kg twice daily was effective in reduc-
ing tissue fungal load by 1–2 log10 cfu/g in neutropenic guinea
pigs infected with C. krusei isolates with an MIC of 0.5 mg/L.28
Considering that 10 mg/kg results in a tAUCs of 31 mgh/L and a
protein binding of 45%,29 the PK/PD target in the former study was
around 68 fAUC24/MIC, which is close to the PK/PD target found in
the present study. Voriconazole at 40 mg/kg once daily was effect-
ive in reducing tissue fungal load by 2 and 1 log10 cfu/g compared
with untreated controls of C. krusei isolates with CLSI MICs of 0.125
and 0.25 mg/L, respectively, in grapefruit-fed neutropenic mice.30
Voriconazole has been successfully used for C. krusei infec-
tions,25,31 whereas breakthrough infection of C. krusei isolates has
been reported in patients with trough levels of 0.53 mg/L,26 which
hardly covers most isolates with MICs >0.06 mg/L as shown in the
present study.
Since in vitro data in artificial growth media simulating serum
PK cannot fully compensate for the lack of clinical data, the clinical
significance of the chosen EI50 endpoint, which corresponds to
an 2 log10 cfu/mL increase from the initial inoculum for azoles
and Candida species, is unknown. Usually, stasis or 1 log kill is used,
although again with no solid support for the clinical significance
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Figure 5. PTA for 5000 patients receiving standard voriconazole dosages of 4 mg/kg IV twice daily for which the AUCs were simulated with Monte
Carlo analysis for different EUCAST and CLSI MICs. Broken lines around the PTA curve represent the 95% CI calculated using the 95% CI limit of
EI50 obtained from non-linear regression analysis of exposure–effect relationships for each Candida species. The horizontal broken line represents
95% PTA. The epidemiological cut-off values for EUCAST (ECOFF) and CLSI (ECV) are shown for each species.
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of those effects. The 2 log10 cfu/mL increase from the initial inocu-
lum is further supported by the clinical AUC/MIC PD target of 100
for fluconazole,32,33 which corresponds to a 1–2 log10 cfu/kidney in-
crease from the initial inoculum in neutropenic animals.34 One
explanation might be the absence of neutrophils both in in vitro
and in neutropenic animal studies that usually exist in patients
with invasive candidiasis, particularly in ICU patients. Indeed
in vivo studies in neutropenic and non-neutropenic mice showed
that median survival was prolonged and fungal load in kidney
decreased by 1 log10 cfu, whereas fluconazole reduced the
fungal load by a further 1 log10 cfu in non-neutropenic mice
compared with neutropenic mice.35 In addition, voriconazole
increased phagocytosis of Candida conidia by monocytes/poly-
morphonuclear leucocytes.36 Thus, the 2 log10 cfu/mL increase
from the initial inoculum in preclinical neutropenic models for
azoles may result in clinical stasis.
The PK/PD breakpoints determined for C. glabrata and C. krusei
for EUCAST (0.125 mg/L) and CLSI (0.06 mg/L) are symmetrical to
the WT MIC distributions of both methodologies since they are two
to three 2-fold dilutions lower than EUCAST epidemiological cut-
off values (1 mg/L for both species) and CLSI epidemiological cut-
off values (0.25 mg/L for C. glabrata and 0.5 mg/L for C. krusei). Of
note, weighted analysis of C. glabrata MIC WT distribution indi-
cated a CLSI epidemiological cut-off value of 0.5 mg/L,27 which
increases symmetry of current PK/PD breakpoints for both species
and methodologies. The PK/PD breakpoints cut exactly in the
middle the WT C. glabrata MIC distribution and at the left side of
the WT C. krusei MIC distribution for both EUCAST and CLSI meth-
odologies. This implies that 47% of C. glabrata and 85% of C. krusei
WT isolates with EUCAST MICs of 0.25–1 mg/L in previously pub-
lished MIC distributions8 will be above the PK/PD breakpoint and,
similarly, 31% (35% based on 0.5 mg/L CLSI epidemiological cut-
off value) of C. glabrata and 79% of C. krusei WT isolates with CLSI
MICs of 0.125–0.25 and 0.125–0.5 mg/L, respectively, in previously
published CLSI MIC distributions.17 In addition, the modal MICs for
EUCAST and CLSI MIC distributions differ by one 2-fold dilution
(Figure 5), with the CLSI modal MIC being lower than the EUCAST
modal MIC,37,38 further supporting the one dilution lower PK/PD
susceptibility breakpoint of CLSI compared with EUCAST. However,
one should also take into account the lower virulence of C. krusei
compared with C. glabrata39 that may affect in vivo PD.
In conclusion, the present study suggests that voriconazole
cannot be recommended for C. glabrata and C. krusei infections
since the probability of attaining the PK/PD targets determined
in the study is too low. The corresponding PK/PD targets for
C. glabrata and C. krusei are 50–80 fAUC24/MIC, resulting in a PK/PD
susceptibility breakpoint of 0.125 mg/L for EUCAST and
0.06 mg/L for CLSI methodologies bisecting WT MIC distributions.
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Figure 6. Correlation between voriconazole trough concentrations in human serum and EUCAST/CLSI MICs of C. glabrata and C. krusei in order to at-
tain the corresponding PK/PD targets of 49 and 52 for EUCAST and 55 and 80 for CLSI, respectively. Error bars represent 95% CI.
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Isolates with EUCAST and CLSI MICs >1 and >0.5 mg/L, respective-
ly, should be considered resistant as toxic levels would be required
to attain the PK/PD targets. For C. glabrata and C. krusei WT isolates
with intermediate EUCAST/CLSI MICs of 0.25–1/0.125–0.5 mg/L,
TDM will be required to optimize drug exposure targeting trough
levels of 1–4 mg/L. However, due to the inherent variation in the
susceptibility testing methods, in practice all WT isolates would re-
quire TDM to ensure that PK/PD targets are attained targeting
trough concentrations of >4 mg/L that will cover up to EUCAST and
CLSI epidemiological cut-off values. This may be difficult in clinical
practice because of a narrow therapeutic window (4–5.5 mg/L)
and the large interindividual and interoccasion variability requiring
real-time TDM and dose adjustment40 when no other alternatives
exist (e.g. echinocandin-resistant infection in patients with kidney
injury) or when a patient should be discharged with an oral ther-
apy. However, those levels would be even more difficult to attain
with the oral formulation (300 mg q12h) in haematological
patients because of the 65% oral bioavailability.19 Since MIC clinic-
al outcome data for C. glabrata and C. krusei species are difficult to
collect, the findings of the present study provide a unique oppor-
tunity to propose PK/PD breakpoints and help define the role of
voriconazole in the management of those infections.
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